Evaluating Dexamethasone as Adjunct Therapy in Pediatric Pneumococcal Meningitis

Overview

Dexamethasone is established as an adjunct treatment for Haemophilus influenzae type b meningitis in children, but its use in pediatric Streptococcus pneumoniae meningitis remains controversial. This review highlights that despite limitations in pediatric studies, adult data strongly support dexamethasone's benefit in reducing mortality and neurological complications in pneumococcal meningitis. The inflammatory mechanisms and steroid effects appear consistent across ages, endorsing dexamethasone use in children with pneumococcal meningitis.

Background

Bacterial meningitis in children historically involved Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, and Neisseria meningitidis as primary pathogens. The introduction of conjugate vaccines has reduced Hib cases dramatically, but pneumococcal meningitis remains a significant cause of morbidity and mortality. The inflammatory response to bacterial cell wall components differs between gram-positive organisms like S. pneumoniae and gram-negative bacteria such as Hib, influencing disease severity and treatment response. Adjuvant dexamethasone therapy aims to mitigate harmful inflammation without compromising bacterial clearance.

Data Highlights

Mortality rates in pediatric bacterial meningitis in the US range from 7% to 10%, with adults experiencing 15% to 37% mortality depending on the causative organism. Prior to conjugate vaccines, Hib caused approximately 20,000 invasive disease cases annually, including 10,000 meningitis cases. Neurologic complications affect 15% to 40% of survivors, with additional intellectual impairments in 10% to 20% of children.

Key Findings

• Dexamethasone reduces brain edema, intracranial pressure, and inflammatory cytokines (TNF-α, IL-1β) in bacterial meningitis models.
• In children with Hib meningitis, dexamethasone improves cerebrospinal fluid parameters, including lower IL-1β and lactate and higher glucose levels.
• Meta-analyses on dexamethasone use in pediatric pneumococcal meningitis are limited by small sample sizes and study heterogeneity.
• Adult studies provide compelling evidence that dexamethasone improves mortality and neurologic outcomes in pneumococcal meningitis.
• The inflammatory response to S. pneumoniae and steroid effects appear similar across age groups, supporting pediatric use.
• Dexamethasone stabilizes vascular endothelium, reducing vasodilation, permeability, and cerebral edema, which are key in meningitis pathophysiology.

Clinical Implications

Clinicians should consider dexamethasone as adjunctive therapy in children with pneumococcal meningitis to potentially reduce mortality and neurologic sequelae, paralleling adult treatment benefits. Early administration before or with the first antibiotic dose is critical to maximize anti-inflammatory effects. Awareness of the distinct inflammatory pathways in pneumococcal meningitis supports tailored steroid use to improve outcomes.

Conclusion

Despite limited pediatric-specific data, the pathophysiologic rationale and adult evidence endorse dexamethasone use in children with pneumococcal meningitis. Incorporating dexamethasone may improve survival and reduce neurologic complications in this serious infection.

References

1. Article Abstract 2024 -- Evaluating Dexamethasone as an Adjunct Treatment for Pediatric Bacterial Meningitis